Zysis is a privately-owned pharmaceutical company optimizing therapies for disorders of the Central Nervous system. It is funded by Catapult Venture Capital.
Zysis is currently developing new treatments for Anxiety disorders and Psychoses/Major Depressive Disorder. In recent times, anxiety conditions have been defined more precisely and it is now clear that these conditions can be present in up to 7% of the population. Therapies that actually have an indication for any anxiety disorder remain few. Zysis therefore sees anxiety as an area of high unmet medical need, and an excellent opportunity.
Zysis has taken a molecule with an excellent efficacy profile and reformulated it through novel controlled-release technology to create a product with a reduced side effect profile, improved compliance and therefore better real-world effectiveness.
The Psychoses remain an area of high unmet need - Schizophrenia, Schizoaffective Disorder and Bipolar Disorders all remain conditions that are difficult to diagnose and to treat effectively. One of the main areas of difficulty is achieving high levels of compliance amongst patients. Any treatment that helps patients comply with therapy and therefore remain symptom-free is another area of opportunity.
Zysis is reformulating an effective anti-psychotic molecule to make it an ultra-controlled release, once-weekly maintenance phase therapy. This improvement in dosing convenience could dramatically reduce the costs for community-based nurses to visit patients daily and at the same time improve patient compliance.